Series A Junior Participating Preferred Stock [Member] Series A junior participating preferred stock. Series A junior participating preferred stock Convertible Notes Due 2016 Convertible Notes Due 2016 [Member] Represents convertible senior notes, which will mature in 2016. Discounted Cash Flow Valuation Technique [Member] Discounted Cash Flow Discounted cash flow valuation technique used to measure fair value. The exclusive legal right granted by the government to the owner of the patent and technology to exploit an invention or a process or a technology for a period of time specified by law and which also includes information related to rights acquired through the registration of a business name to gain or protect exclusive use thereof. Technology, Patents and Trade Names [Member] Technology, patents and tradenames Customer Relationships and Non Compete Agreements [Member] An asset acquired in a business combination representing a customer relationship that exists between an entity and its customer if (a) the entity has information about the customer and has regular contact with the customer, and (b) the customer has the ability to make direct contact with the entity. Such assets would include tenant relationships obtained through acquisition, unless otherwise included in acquired in-place leases. It also includes the payments made to third parties in exchange for their agreement not to engage in specified competitive practices in specified geographic territories for a specified period of time. Customer relationships and non-compete agreements Finite-Lived Contract Based Intangible Assets [Member] Represents the details pertaining to contract-based intangible assets which consisted of a license agreement. Contract-based Award Type [Axis] Share Tracking Awards Plan [Member] Share tracking award plans (STAP) is a long-term, equity-based compensation plan for eligible participants. Awards granted under this plan are non-dilutive as they are not settled in shares of entity's common stock and convey the right to receive in cash an amount equal to the appreciation of entity's common stock. Share tracking award plans (STAP) Share Tracking Awards Plan 2008 [Member] 2008 share tracking awards plan (STAP) The 2008 share tracking awards plan (STAP) is a long-term, equity-based compensation plan for eligible participants. Awards granted under this plan are non-dilutive as they are not settled in shares of entity's common stock and convey the right to receive in cash an amount equal to the appreciation of entity's common stock. Fair Value by Asset or Liability Class [Axis] Fair value information by class of asset or liability. Contingent Consideration [Member] Potential payments under the contingent consideration arrangement, including cash and shares as applicable. Contingent consideration Amendment Description Selling, General and Administrative Expense [Member] Costs related to selling a firm's product and services, as well as all other general and administrative expenses. Selling, general and administrative Amendment Flag Document and Entity Information Lease obligation-current Lease Financing Obligation Current This element represents current portion of the carrying amount of a long-term financing obligation structured as a synthetic lease arrangement as of the balance sheet date. Lease Financing Obligation Lease obligation The carrying amount of a long-term financing obligation structured as a synthetic lease arrangement as of the balance sheet date. Fair Value Assets Measured on Recurring Basis Put Option, Current Other current assets measured under the fair value option (in dollars) This element represents a certain statement of financial position current asset caption which represents a class of assets, or which may include an individual asset, measured at fair value on a recurring basis. Other assets measured under the fair value option (in dollars) Fair Value Assets Measured on Recurring Basis Put Option This element represents a certain statement of financial position asset caption which represents a class of assets, or which may include an individual asset, measured at fair value on a recurring basis. Sum of operating profit and nonoperating income (expense) including income (loss) from equity method investments, before income taxes, extraordinary items, cumulative effects of changes in accounting principles, and noncontrolling interest. Income (Loss) before Income Taxes Income before income tax Provision for Doubtful Accounts and Inventory Write-down Provision for inventory obsolescence Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected). This element also includes a charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions. License Costs Incurred but Not Paid Costs incurred, but not yet paid, that are directly related to obtaining license rights. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Expense associated with outstanding license fees Income Tax Cash Flows Current and deferred tax expense (benefit) Income tax expense (benefit) pertaining to the entity's operations. Payments of Convertible Debt Hedge and Warrants, Net Payment for convertible note hedge and warrants, net Represents the cash outflow with respect to payments for convertible note hedge and warrants, net. Represents the cash outflow with respect to the payment for accelerated share repurchase transaction cost. Payment for an accelerated share repurchase transaction (Note 10) Payment for an Accelerated Share Repurchase Transaction Cost Lease obligation incurred Noncash change in the carrying amount of a long-term financing obligation structured as a synthetic lease arrangement. Increase (Decrease) Lease Financing Obligation Basis of Presentation Stockholders' Equity Disclosures related to statement of shareholders' equity, including earnings per share and stock options disclosure. Comprehensive Income is included in a separate statement to the financial statements. Stockholders Equity Note Excluding Comprehensive Income Disclosure [Text Block] Litigation Current Fiscal Year End Date Fair Value Assets and Liabilities Measured on Recurring Basis Unobservable Input Reconciliation [Table Text Block] Reconciliation of the beginning and ending balances of Level 3 liabilities Tabular disclosure of the fair value measurement of assets and liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets and liabilities) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets and liabilities) are reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset and liability. Summary of assumptions to estimate the fair value of share tracking awards Tabular disclosure of the significant assumptions used during the year to estimate the fair value of share-based awards, including but not limited to: (a) expected term of the share-based awards, (b) expected volatility of the entity's shares, (c) expected dividends, and (d) risk-free rate(s). Schedule of Share-based Payments Award Other than Options Valuation Assumptions [Table Text block] Components of interest expense of convertible debt Tabular disclosure of interest expense related to convertible debt. Schedule of Interest Expense on Convertible Debt [Table Text Block] Schedule of Convertible Debt [Table Text Block] Information about carrying amount of convertible debt Tabular disclosure of the carrying amount related to the convertible debt. Schedule of Interest Expense [Table Text Block] Components of interest expense Tabular disclosure of the components of interest expense during the period. Tabular disclosure of employee and non-employee stock option exercise data. Schedule of Service Share-based Compensation, Employee and Nonemployee Stock Option Exercise Data [Table Text Block] Summary of employee and non-employee stock option exercise data Segment Reporting Gross Profit of Commercial Products [Table Text Block] Tabular disclosure of revenues, cost of revenues and gross profit for each commercial product during the period. Revenues, cost of revenues and gross profit for each commercial product Convertible Notes Due 2011 Convertible Notes Due 2011 [Member] Represents convertible senior notes, which matured in 2011. Business Acquisition, Contingent Consideration, Fair Value Disclosure Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement including cash and shares. Contingent consideration Fair Value Inputs Cost of Debt and Weighted Average Cost of Capital Discount Rate Cost of debt and weighted average cost of capital (as a percent) Represents interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value relating to contingent consideration. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt. Business Acquisition, Contingent Consideration, Maximum Potential Cash Payment Maximum amount of potential cash payments that could result from the contingent consideration arrangement. Contingent consideration-Tyvaso Inhalation System acquisition, maximum potential cash payments Document Period End Date Fair Value Inputs Previous Cost of Debt and Weighted Average Cost of Capital Discount Rate Previous cost of debt and weighted average cost of capital (as a percent) Represents previous interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value relating to contingent consideration. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt. Fair Value Assets (Liabilities) Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Summarization of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets and liabilities using significant unobservable inputs (Level 3). Fair Value by Asset or Liability Class [Domain] Represents classes of assets or liabilities measured and disclosed at fair value. Fair Value Assets (Liabilities) Measured on Recurring Basis Unobservable Input Reconciliation [Line Items] Level 3 financial assets and liabilities carried at fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset (Liability) Gains (Losses) Realized (Unrealized) [Abstract] Total gains/(losses) realized/unrealized: This element represents total unrealized gains or losses for the period included in earnings arising from liabilities still held at the reporting date that are measured at fair value on a recurring basis using unobservable inputs (Level 3). Amount of total gains/(losses) for the period included in earnings attributable to the change in unrealized gains or losses related to outstanding liabilities Fair Value Measurement with Unobservable Inputs Reconciliation Recurring Basis Liability Still Held Gain (Loss) Included in Earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset (Liability) Settlements Settlements that have taken place during the period in relation to net assets and liabilities measured at fair value and categorized within Level 3 of the fair value hierarchy. Settlements Fair Value Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset (Liability) Net Value This element represents a net asset liability measured at fair value using significant unobservable inputs (Level 3) which is required for reconciliation purposes of beginning and ending balances. Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset (Liability) Still Held Gain (Loss) Included in Earnings This element represents total unrealized gains or losses for the period included in earnings arising from assets and liabilities still held at the reporting date that are measured at fair value on a recurring basis using unobservable inputs (Level 3). Amount of total gains/(losses) for the period included in earnings attributable to the change in unrealized gains or losses related to the outstanding liability Held-to-maturity Securities, Debt Maturities in One Year Through Two Years, Net Carrying Amount This item represents debt securities, at cost, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments, as defined), and fair value hedge accounting adjustments, if any, which are expected to mature after one year and through two years from the balance sheet date and which are categorized as held-to-maturity. Due in one to two years, Amortized Cost Due in three to five years, Amortized Cost This item represents debt securities, at cost, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments, as defined), and fair value hedge accounting adjustments, if any, which are expected to mature after two years and through five years from the balance sheet date and which are categorized as held-to-maturity. Held-to-maturity Securities, Debt Maturities in Three Years Through Five Years, Net Carrying Amount Held-to-maturity Securities, Debt Maturities after Five Years, Net Carrying Amount Represents debt securities, at cost, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments, as defined), and fair value hedge accounting adjustments, if any, which are expected to mature after five years from the balance sheet date and which are categorized as held-to-maturity. Due after five years, Amortized Cost This item represents the fair value of debt securities which are expected to mature after one year and through two years from the balance sheet date and which are categorized as held-to-maturity. Due in one to two years, Fair Value Held-to-maturity Securities, Debt Maturities in One Year Through Two Years, Fair Value Held-to-maturity Securities, Debt Maturities in Three Years Through Five Years, Fair Value This item represents the fair value of debt securities which are expected to mature after two years and through five years from the balance sheet date and which are categorized as held-to-maturity. Due in three to five years, Fair Value Represents the fair value of debt securities which are expected to mature after five years from the balance sheet date and which are categorized as held-to-maturity. Due after five years, Fair Value Held-to-maturity Securities, Debt Maturities after Five Years, Fair Value The entity owns less than this percentage of common stock of an available-for-sale investee. Available-for-sale investment in common stock, less than a certain percentage Available-for-Sale Securities, Equity Securities Investment Percentage Less Than Goodwill and Other Intangibles Assets, Gross Sum of gross carrying amounts of all intangible assets including goodwill before accumulated amortization as of the balance sheet date. Total intangible assets, Gross Share Tracking Awards Plan 2011 [Member] The 2011 share tracking awards plan (STAP) is a long-term, equity-based compensation plan for eligible participants. Awards granted under this plan are non-dilutive as they are not settled in shares of entity's common stock and convey the right to receive in cash an amount equal to the appreciation of entity's common stock. 2011 share tracking awards plan (STAP) Share-based Compensation Arrangement by Share-based Payment Award, Increase in Number of Authorized Shares Available for Grant Increase in total number of awards available for grant (in shares) Represents the increase in total number of authorized awards available for grant under the award plan. Share-based Compensation Arrangement by Share-based Payment Award Decrease in Number of Authorized Shares Available for Grant Decrease in total number of awards available for grant (in shares) Represents the decrease in total number of authorized awards available for grant under the award plan. Share-based Award Compensation Liability Represents the estimated fair value of share-based awards at the end of the reporting period that are accounted for as a liability due to cash settlement provisions. Equity based compensation liability Share-based Compensation Arrangement by Share-based Payment Award, Other than Options Fair Value Assumptions Risk Free Interest Rate Risk-free interest rate (as a percent) The risk-free interest rate assumption that is used in valuing an award based upon its own shares. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate Forfeiture rate (as a percent) The weighted average forfeiture rate assumption used by an entity in valuing an award based upon its own shares. The expected forfeiture rate may be derived from historical employee turnover rates and expectations about the future. Expected forfeiture rate (as a percent) The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the award's term. Share-based Compensation Arrangement by Share-based Payment Award, Other than Options Fair Value Assumptions Expected Dividend Rate Expected dividend yield (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Outstanding [Roll Forward] A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Share-based awards activity Share-based Compensation Arrangement by Share-based Payment Award Equity Instruments Other than Options Outstanding Number Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) The number of units under share-based plans other than stock option plans awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested awards. Number of share-based units exercised during the current period. Share-based Compensation Arrangement by Share-based Payment Award Equity Instruments Other than Options Exercised in Period Exercised (in shares) The number of units under share-based plans other than stock option plans awarded under the plan that validly exist and are outstanding and vested as of the balance sheet date. Share-based Compensation Arrangement by Share-based Payment Award Equity Instruments Other than Options Exercisable Number Exercisable at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest Number The number of units awarded under share-based plans other than stock option plans that validly exist and are outstanding which are expected to vest as of the balance sheet date. Expected to vest at the end of the period (in shares) Share awards, Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Additional Disclosures [Abstract] Outstanding at the end of the period (in dollars per share) The weighted average exercise price of outstanding awards at the balance sheet date. Share-based Compensation Arrangement by Share-based Payment Award Other than Options Outstanding Weighted Average Exercise Price Outstanding at the beginning of the period (in dollars per share) Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award Other than Options Grants in Period Weighted Average Exercise Price The weighted average exercise price as of the balance sheet date on units awarded under the plan during the reporting period. Exercised (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award Other than Options Exercises in Period Weighted Average Exercise Price The weighted average price at which award holders exercised their awards under the plan during the reporting period. Forfeited (in dollars per share) The weighted average price at which grantees could have exercised with respect to awards that were terminated during the reporting period due to noncompliance with plan terms during the reporting period. Share-based Compensation Arrangement by Share-based Payment Award Other than Options Forfeitures in Period Weighted Average Exercise Price Exercisable at the end of the period (in dollars per share) The weighted-average price as of the balance sheet date on vested portions of awards outstanding and currently exercisable under the awards plan. Share-based Compensation Arrangement by Share-based Payment Award Other than Options Exercisable Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award Other than Options Expected to Vest Outstanding Weighted Average Exercise Price Expected to vest at the end of the period (in dollars per share) As of the balance sheet date, the weighted-average exercise price for outstanding awards that are expected to vest. Share-based Compensation Arrangement by Share-based Payment Award, Other than Options Weighted Average Remaining Contractual Term Disclosures [Abstract] Share awards, Weighted Average Remaining Contractual Term Exercisable at the end of the period The weighted average period between the balance sheet date and expiration for all vested portions of awards outstanding and currently exercisable (or convertible) under the plan, which may be expressed in a decimal value for number of years. Share-based Compensation Arrangement by Share-based Payment Award Other than Options Exercisable Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term The weighted-average period between the balance sheet date and expiration date for outstanding awards that are expected to vest, which may be expressed in a decimal value for number of years. Expected to vest at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Aggregate Intrinsic Value Disclosures [Abstract] Share awards, Aggregate Intrinsic Value As of the balance sheet date, the total dollar difference between fair values of the underlying shares indexed and exercise prices of outstanding awards. Outstanding at the end of the period (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Outstanding, Intrinsic Value Exercisable at the end of the period (in dollars) The total dollar difference between fair values of the underlying shares indexed under the plan and exercise prices of vested portions of awards outstanding and currently exercisable under the award plan as of the balance sheet date. Share-based Compensation Arrangement by Share-based Payment Award Other than Options Exercisable Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value As of the balance sheet date, the total dollar difference between fair values of the underlying shares indexed and exercise prices of outstanding awards that are expected to vest. Expected to vest at the end of the period (in dollars) Awards available for issuance (in shares) The number of awards available for issuance under the plan as of the balance sheet date. Share-based Compensation Arrangement by Share-based Payment Award, Number of Awards Available for Issuance Represents the number of share tracking award plans. Number of Share Tracking Awards Plans Number of share tracking award plans Debt Instrument Conversion Obligation Trading Day Period Assessed Represents the number of days in consecutive trading-day period ending on the last trading day of the quarter that is used to determine if the contingent conversion requirement is met. Trading-day period used to determine contingent conversion requirement on notes The number of equity instruments upon which the aggregate consideration, both in cash and stock, is determined for conversion. Convertible debt, number of shares into which convertible Debt Instrument, Convertible, Number of Equity Instruments Aggregate Consideration Determined Percentage of closing sales price of the entity's common stock that conversion price must exceed in order for notes to be convertible Represents the percentage of the closing sale price of the entity's common stock for at least 20 days within 30 consecutive trading days that the closing sales price of the entity's common stock must exceed the conversion price in order for the debt instruments to be convertible. Debt Instrument Conversion Obligation Common Stock Closing Sales Price as Percentage of Conversion Price Number of trading-days within 30 consecutive trading days in which closing price of the entity's common stock must exceed conversion price for notes to be redeemable Represents the number of trading-days within a period of 30 consecutive trading days the closing price of the entity's common stock must exceed the applicable conversion price in order for the debt instruments to be convertible. Debt Instrument Conversion Obligation Common Stock Closing Sales Price Number of Trading Days Number of consecutive trading days immediately after any five consecutive trading-day period during note measurement period. Debt Instrument Conversion Obligation Number of Consecutive Trading Days after Consecutive Trading Day Period Number of consecutive business days immediately after any five consecutive trading-day period during note measurement period Number of consecutive trading-days during which the trading price of the convertible notes must be less than a given percentage of the entity's stock price Number of consecutive trading days during which the trading price of the convertible notes is less than a specific percentage of the conversion price of the convertible notes. Debt Instrument Conversion Obligation Period of Consecutive Trading Days Debt Instrument Conversion Obligation Trading Price as Percentage of Product of Last Reported Common Stock Sale Price and Conversion Rate Maximum Percentage of trading price to product of last reported sale price of the entity's common stock and conversion rate, maximum Represents the maximum percentage of the trading price of each debt instrument to the product of the last reported sale price of the entity's common stock and the conversion rate of the debt instrument that the trading price must be less than in order for the debt instruments to be convertible. Represents the redemption price of long-term debt as a percentage of its principal value in the case of redemptions, at the election of debt holders, due to a change in control. Redemption Price of Debt as Percentage of Principal Amount Redemption price of convertible notes as a percentage of principal amount, due to change in control Accounting Policies [Abstract] Convertible Debt Amount of Equity Component The carrying amount of the equity component of convertible notes representing the conversion feature. Equity component Debt Instrument Amortization Period Amortization schedule Represents the amortization period for the debt instrument. Entity Well-known Seasoned Issuer Convertible Senior Notes [Abstract] Carrying amount related to convertible notes Entity Voluntary Filers Accumulated amortization of debt discount at the end of the reporting period. Debt Instrument, Accumulated Amortized Discount Discount accumulated amortization Entity Current Reporting Status Debt, maturity term Debt Instrument Maturity Term Represents the period from the issuance of the debt instrument to scheduled repayment. Entity Filer Category Period Used in Computation of Annual Principal Payments Amortization schedule, period for calculation of principal payments Represents the amortization period used in the calculation of annual principal payments of debt. Entity Public Float Interest Rate Used in Computation of Annual Principal Payments Represents the fixed interest rate used in the calculation of annual principal payments of debt. Amortization schedule, fixed interest rate for calculation of principal payments (as a percent) Entity Registrant Name Debt Instrument Alternative Interest Rate Terms Description of the alternative interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets. Debt, interest rate terms, alternative option Entity Central Index Key Debt Instrument, Alternative Interest Rate Option Represents the alternative interest based on an option. Debt, interest rate, alternative option (as a percent) Debt Instrument, Alternative Interest Rate, Option Spread Over Federal Funds Effective Rate Represents the spread over the federal funds effective rate added to the alternative interest based on an option. Debt, interest rate, alternative option, spread over federal funds effective rate (as a percent) Debt, interest rate, alternative option, basis Debt Instrument, Alternative Interest Rate Option Basis Represents the basis for the rate added to the alternative interest based on an option. Debt Instrument, Alternative Interest Rate Option Spread Represents the spread over the basis for the rate added to the alternative interest based on an option. Debt, interest rate, alternative option, spread over basis (as a percent) Entity Common Stock, Shares Outstanding Loan Prepayment Penalty within First Six Months of Term Percentage of Loan Balance Debt, prepayment premium within first six-months of the term, percentage of loan balance Percentage of loan balance premium if the debt is prepaid within first six-months of the term. Loan Prepayment Penalty Successive Six Month Intervals Decline in Percentage of Loan Balance Debt, prepayment premium, successive six-month intervals, decline in percentage of loan balance Decline in the percentage of loan balance premium if the debt is prepaid, per successive six month intervals, following the initial six months of the term. Debt Instrument, Financial Covenant Consolidated Leverage Ratio, Numerator Maximum consolidated leverage ratio, numerator Represents the numerator portion of maximum consolidated leverage ratio. Debt Instrument Financial Covenant Maximum Consolidated Leverage Ratio Consolidated leverage ratio Represents the numerator portion of consolidated leverage ratio. Debt Instrument, Financial Covenant Consolidated Leverage Ratio, Denominator Maximum consolidated leverage ratio, denominator Represents the denominator portion of maximum consolidated leverage ratio. Debt Instrument, Financial Covenant Measurement Period Financial covenants, measurement period Represents the measurement period for financial covenants. Debt Instrument, Financial Covenants, Minimum Liquidity Amount Financial covenants, minimum liquidity amount Represents the minimum liquidity amount for financial covenants. Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Debt Instrument, Financial Covenants, Qualification Amount for Minimum Liquidity Financial covenants, qualification amount for minimum liquidity Represents the qualification amount for minimum liquidity of financial covenants. Convertibility of Debt Trading Price of Debt Test Number of Consecutive Trading Days Debt will be Convertible Convertibility of debt, trading price of debt test, length of consecutive trading day period that debt will be convertible When testing, based upon the trading price of the debt, whether convertible debt may be converted by the debt holder, represents the number of consecutive trading days the debt will be convertible if the price of the debt stays below the calculated target for the required amount of days. Convertibility of Debt Trading Price of Debt Test Number of Consecutive Trading Days Price Must Remain Below Calculated Target When testing, based upon the trading price of the debt, whether convertible debt may be converted by the debt holder, represents the number of consecutive trading days the debt price must stay below the calculated target. Convertibility of debt trading price of debt test, length of consecutive trading-day period that the trading price of the debt must not exceed calculated target Convertibility of debt, trading price of debt test, percentage of closing price of stock used to multiply by number of shares underlying debt (as a percent) Convertibility of Debt Trading Price of Debt Test Percentage of Closing Stock Price Used in Calculation of Target When testing, based upon the trading price of the debt, whether convertible debt may be converted by the debt holder, represents the percentage of the closing stock price which is multiplied by the number of shares underlying the debt in order to calculate the target that the debt price must stay below. Debt Instrument Conversion Obligation Number of Consecutive Trading Days Used to Determine Aggregate Conversion Value Number of consecutive trading days used to determine aggregate conversion value of notes Represents the number of consecutive trading days which were used to determine the aggregate conversion value of debt instruments that have matured. Debt Instrument, Aggregate Conversion Value in Excess of Par Value Amount by which aggregate conversion value exceeds par value Represents the amount by which the aggregate conversion value of the debt instrument as of the balance sheet date exceeds the par value. Call Option Purchase [Abstract] Purchase of call options Payments for Call Option Call option, payment The cash outflow associated with the amount paid for call option, which was recorded as a reduction to additional paid-in-capital. Sale of warrant Warrants [Abstract] Purchased Call Options and Warrants Net Cost The net cost of purchased call options and sale to counterparty warrants in connection with the issuance of the 2016 Convertible Notes. Net cost of purchased call options and sale of warrants Document Fiscal Year Focus Common stock received from the bank which were obtained from existing shareholders (in shares) Represents the common stock received from the bank which were obtained from existing shareholders. Purchase of Common Stock Shares Document Fiscal Period Focus Share warrant, reserved for settlement Shares reserved for the settlement of the warrant by the entity. Shares Reserved for Settlement of Warrant Represents proceeds received in exchange for providing the holder a warrant to purchase shares of the entity's common stock. Share warrant, proceeds Proceeds Received from Warrant Call Option Settlement Period Settlement period Represents the settlement period of call options. Class of Warrant or Right Strike Price as Percentage of Initial Conversion Price Strike price as a percentage of initial conversion price Represents the strike price as a percentage of initial conversion price under sale of warrant. Represents the percentage of excess of strike price over initial conversion price under sale of warrant. Class of Warrant or Right Excess of Strike Price Over Initial Conversion Price as Percent Percentage of excess of strike price over initial conversion price Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Number The number of unvested share options that are expected to vest as of the balance sheet date. Expected to vest at the end of the period (in shares) Expected to vest at the end of the period, Weighted-Average Exercise Price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award Options Expected to Vest Outstanding Weighted Average Exercise Price As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are expected to vest. Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term Disclosures [Abstract] Stock options, Weighted Average Remaining Contractual Term Share awards, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term The weighted-average period between the balance sheet date and expiration date for outstanding awards that are expected to vest, which may be expressed in a decimal value for number of years. Expected to vest at the end of the period, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value Disclosures [Abstract] Stock options, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value As of the balance sheet date, the total dollar difference between fair values of the underlying shares reserved for issuance and exercise prices of expected to vest options outstanding. Expected to vest at the end of the period, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments, Options Vested in Period, Total Fair Value Total fair value of vested employee options The total fair value of equity-based payment equity instruments, which vested during the reporting period as calculated by applying the disclosed pricing methodology. Document Type Share Repurchase Stock Repurchase [Abstract] Estimated Annual Effective Income Tax Rate Estimated annual effective tax rates (as a percent) Represents the estimated annual effective tax rate which is based on annual projections of pre-tax earnings and related taxes. Noncurrent Federal Tax Expense (Benefit) Federal The component of other non-current income tax expense benefit primarily related to share-based compensation for the period representing amounts paid or payable (or refundable) after one year as determined by applying the provisions of enacted federal tax law to the domestic taxable income or loss from continuing operations. Noncurrent State and Local Tax Expense (Benefit) State The component of other non-current income tax expense benefit primarily related to share-based compensation for the period representing amounts paid or payable (or refundable) after one year as determined by applying the provisions of enacted state and local tax law to relevant amounts of taxable income or loss from continuing operations. Accounts Receivable, Net, Current Accounts receivable, net of allowance of none for 2012 and 2011 Noncurrent Foreign Tax Expense (Benefit) Foreign The component of other non-current income tax expense benefit primarily related to share-based compensation for the period representing amounts paid or payable (or refundable) after one year as determined by applying the provisions of foreign enacted tax law to the foreign taxable income or loss from continuing operations. Noncurrent Income Tax Expense (Benefit) Total other The component of other non-current income tax expense benefit primarily related to share-based compensation for the period representing amounts of income taxes paid or payable (or refundable) after one year for the period for all income tax obligations as determined by applying the provisions of relevant enacted tax laws to relevant amounts of taxable income or loss from continuing operations. Commercial Products Number Number of commercial products The number of commercial products of the entity. Schedule of Revenue, Cost of Revenue Gross Profit by Product [Table] A table disclosing the revenue, cost of revenue and gross profit by commercial product. Remodulin Remodulin [Member] Represents Remodulin, a commercial product of the entity, for treating pulmonary arterial hypertension (PAH). Tyvaso Tyvaso [Member] Represents Tyvaso, a commercial product of the entity, for treating pulmonary arterial hypertension (PAH). Adcirca [Member] Represents Adcirca, a commercial product of the entity, for treating pulmonary hypertension. Adcirca Revenue Cost of Revenue, Gross Profit by Product [Line Items] Revenues, cost of revenues and gross profit Entity-Wide Revenue, Major US Based Distributors Number Number of U.S.-based distributors that account for majority of the entity's revenues. Number of U.S.-based distributors for majority of the entity's revenues Entity-Wide Revenue, Major US Based Distributors Percentage Percentage of revenues from U.S. based distributors that account for majority of the entity's revenues. Percentage of revenues from U.S.-based distributors for majority of the entity's revenues Loss Contingency Number of Days from Receipt of Notice Letter to Commence Patent Infringement Lawsuit Number of days from receipt of Notice Letter to commence patent infringement lawsuit against Sandoz Represents the number of days from receipt of Notice Letter to commence patent infringement lawsuit. Loss Contingency Period for Which Lawsuit Would Preclude FDA from Approving ANDA Maximum period for which lawsuit would preclude the FDA from approving Sandoz's ANDA Represents the maximum period for which lawsuit would preclude the FDA from approving an Abbreviated New Drug Application (ANDA). Loss Contingency Number of Patents Listed in Orange Book Number of patents listed in the Orange Book Represents the number of patents listed in the FDA's Approved Drug Products List (the Orange Book) Shares received as part of Medicomp sale Shares Received upon Sale of Subsidiary Represents the shares received on the sale of the wholly-owned subsidiary of the entity. Shares received as part of sales consideration Shares Received upon Sale of Subsidiary Shares Represents the shares received on the sale of the wholly-owned subsidiary of the entity. Stock Issued During Period, Value, Conversion of Convertible Securities and Shares Received Through Hedge Exercise The gross value of stock issued during the period upon the conversion of convertible securities and the gross value of shares received through the exercise of convertible note hedges. Conversion of 2011 convertible notes and exercise of convertible note hedge Adjustments to Additional Paid in Capital, Convertible Debt Hedge and Warrants, Net 2016 convertible note hedge and warrants, net of tax (Note 8) This element represents the adjustment made to additional paid-in capital due to difference between purchase of call option and sale of warrants. Summary of Significant Accounting Policies Basis of Presentation Consolidation Significant Accounting Policies and Concentration Risk Disclosure [Text Block] This element represents the entire disclosure of consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity, which also includes the entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs about the general nature of the risk associated with the concentration of credit risk, suppliers, products, revenues and customers, and may indicate the percentage of concentration risk as of the balance sheet date. Lease Obligation Lease Financing Obligation [Text Block] Lease Obligation Description of lease obligations related to synthetic lease arrangement. Includes lease terms, assets capitalized under the terms, and periodic interest accretion. Assets and Liabilities Held-for-sale Assets and Liabilities Held-for-sale Disclosure [Text Block] This element represents the disclosure pertaining to the assets and liabilities held for sale during the reporting period by the entity. Assets and Liabilities Held for Sale Distribution Agreements Distribution Agreements Distribution Agreements Disclosure [Text Block] This element represents the disclosure relating to distribution agreements. Disclosures may encompass the contractual responsibilities between supplier and distributor, ordering specifications, inventory requirements and the amounts and timing of fees. Accounts Payable, Current Accounts payable Concentrations of Credit Risk, Products, Revenues and Customers [Policy Text Block] Concentrations of Credit Risk, Products, Revenues and Customers Describes the entity's accounting policy relating to concentrations of credit risk, products, revenues and customers. Pharmaceutical Revenue Net [Member] Represents net pharmaceutical revenue. Net pharmaceutical revenue Accredo Health Group, Inc. [Member] Details pertaining to Accredo health group Inc., being a major customer of the entity. Accredo Health Group, Inc. Number of Distributors Number of distributors Represents the number of distributors. Number of Major Customers Number of major customers Represents the number of major customers. Reclassification Period for Operating Result of Subsidiary Represents the reclassification period for operating results of subsidiary of the reporting entity. Period for reclassification of operating results of Medicomp, Inc. Cash and Cash Equivalents, Maturity Period, Maximum Cash equivalents, maturity period Represents the maximum maturity period of cash equivalents. Buildings, Building Improvements and Leasehold Improvements [Member] Details pertaining to buildings, building improvements and leasehold improvements. Buildings, building improvements and leasehold improvements Furniture, Equipment and Vehicles [Member] Details pertaining to equipments used to produce goods and services. It also includes long-lived, depreciable assets, commonly used in offices and stores and for road transportation. Furniture, equipment and vehicles Medical Equipment [Member] Details pertaining to Holter and event cardiac monitoring systems. Holter and event cardiac monitoring systems Accounts Receivable [Member] Accounts receivable Revenue Recognition [Line Items] Revenue Recognition Shelf Life of Product, Minimum Shelf life of Remodulin and Tyvaso sold to customers, minimum Represents the minimum shelf life of a product. Holding Period of Inventory by Distributor, Low End of Range Inventory holding period of Remodulin and Tyvaso, low end of range Represents the low end of the range of the inventory holding period. Holding Period of Inventory by Distributor, High End of Range Inventory holding period of Remodulin and Tyvaso, high end of range Represents the high end of the range of the inventory holding period. Percentage of Remodulin Exchanges to Total Volume of Vials Sold Maximum Maximum exchanges of Remodulin as compared to the total volume of vials sold (in percent) Represents the maximum percentage of exchanges of Remodulin as compared to the total volume of vials sold. Share-based Compensation Arrangement by Share-based Payment Award Maximum Compensation Contribute For Stock Purchases Percentage Maximum percentage of compensation employees may contribute for purchase of common stock under the ESPP This element represents the maximum percentage of compensation that employees may contribute for purchase of common stock under the employee stock purchase plan. Income Tax [Abstract] Income taxes Percentage of Likelihood of Realization of Recognized Tax Benefit, Minimum Minimum percentage of likelihood of realization of recognized tax benefit Represents the minimum percentage of likelihood of realization of recognized benefit. Accrued Royalties and Rebates, Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties and rebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Royalties and rebates Accrued Research Related Costs, Current Research related Carrying value as of the balance sheet date of obligations incurred through that date and payable for research related costs, used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Schedule of Future Milestone Rental Payments, under Assignment and License Agreements [Table Text Block] Future milestone payments under assignment and license agreements Tabular disclosure of future milestone payments required in the aggregate and for each of the five succeeding fiscal years for assignment and license agreements upon the achievement of certain product development and commercialization goals as of the balance sheet date. Future milestone payments under Assignment and License Agreements Future Milestone Payments Due [Abstract] 2012 For assignment and license agreements in excess of one year, milestone payments due within one year of the balance sheet date. Future Milestone Payments Due, Current Accretion (Amortization) of Discounts and Premiums, Investments Amortization of discount or premium on investments For assignment and license agreements in excess of one year, milestone payments due within the second year of the balance sheet date. Future Milestone Payments, Due in Two Years 2013 Future Milestone Payments Due, in Three Years 2014 For assignment and license agreements in excess of one year, milestone payments due within the third year of the balance sheet date. Future Milestone Payments Due, in Four Years 2015 For assignment and license agreements in excess of one year, milestone payments due within the fourth year of the balance sheet date. Future Milestone Payments, Due in Five Years 2016 For assignment and license agreements in excess of one year, milestone payments due within the fifth year of the balance sheet date. Future Milestone Payments Due, Thereafter Thereafter For assignment and license agreements in excess of one year, milestone payments due after the fifth year of the balance sheet date. Future Milestone Payments, Due Total The total of future contractually required payments on milestone payments under the assignment and license agreements. Oxford Glycobiological Institute [Member] Represents the details pertaining to research agreement with the University of Oxford (Oxford) to develop antiviral compounds. Research under this agreement is performed by Oxford Glycobiological Institute, which is headed by a member of our board of directors and our scientific advisory board. Oxford Glycobiological Institute Royalty as a percentage of net sales Represents the royalty as a percentage of net sales. Royalty as Percentage of Net Sales Research and Development Obligation with Extension of Term Represents the estimated obligation in connection with the extension of the research agreement term. Research obligation in connection with extension of term Number of Equal Installments for Payment of Research and Development Expense Research expense, number of equal installments Represents the number of equal installments for payment of research expense. Share Based Compensation Arrangement by Share Based Payment Award Offering Period Offering period Represents the term of each offering period under the employee stock repurchase plan. Represents the outstanding payable related to the extension of the research agreement. Research and Development Expense, Extension Liability Amount Outstanding Amount payable under research agreement extension Other Development Expenses Other development expenses Represents the other development expenses. Defined Benefit Plan Amounts Recognized in Other Comprehensive Income, Net Actuarial Gain (Loss) before Tax Net unrecognized actuarial (gain) loss The aggregate net actuarial gains or losses recognized in other comprehensive income. Defined Benefit Plan, Accumulated Other Comprehensive Income Tax Amount Tax The tax portion of total of net gain (loss), prior service cost (credit), and transition assets (obligations), as well as minimum pension liability if still remaining, included in accumulated other comprehensive income associated with a defined benefit pension or other postretirement plan(s) because they have yet to be recognized as components of net periodic benefit cost. Defined Benefit Plan Accumulated Other Comprehensive Income Net of Tax Total, net of tax The after tax portion of total of net gain (loss), prior service cost (credit), and transition assets (obligations), as well as minimum pension liability if still remaining, included in accumulated other comprehensive income associated with a defined benefit pension or other postretirement plan(s) because they have yet to be recognized as components of net periodic benefit cost. Defined Benefit Plan Eligibility Age Eligibility age Represents participants' minimum retirement age in order to be eligible to receive benefit payments. Number of Months of Salary Taken as Gross Base for Receipt of Monthly Payments Number of months of salary taken as gross base for receipt of monthly payments Represents the number of months of salary taken as gross base for receipt of monthly payments. Defined Benefit Plan Vesting Period Vesting period of plan, when participants begin receiving payments Represents the vesting period of plan whereupon participants begin receiving payments from the plan. Defined Benefit Plan Expected Future Benefit Payments Total future estimated benefit payments Represents the total estimated amount of benefits expected to be paid. Represents the additional number of new participants. Defined Benefit Plan Additional New Participants Number Additional number of new participants Defined Contribution Plan Employer Matching Contribution Percentage Employer's matching contribution, percentage Represents the percentage of employer's matching contribution. Defined Contribution Plan, Vesting of Matching Contribution, Service Period Period of service for vesting of matching contributions Represents the service period after which the matching contributions vest immediately. Defined Contribution Plan Annual Increments Annual increments for vesting in employer's matching contribution Represents the annual increments for vesting in the employer's matching contribution over a three-year period. Defined Contribution Plan Annual Increments Vesting Period Period over which the matching contribution vest annually Represents the period over which the matching contribution vest annually. Glaxo Smith Kline PLC [Member] Represents the information pertaining to license agreement with GlaxoSmithKline PLC (Glaxo), which has assigned patents and patent applications to the entity. GlaxoSmithKline PLC (Glaxo) Pfizer Inc. [Member] Represents the information pertaining to license agreement with Pfizer Inc. (Pfizer) exclusively licensed the entity to use patents and a patent application. Pfizer Inc. Supernus Pharmaceuticals, Inc. [Member] Represents the information pertaining to license agreement with Supernus Pharmaceuticals, Inc. (Supernus) for use of certain technologies developed by Supernus. Supernus Pharmaceuticals, Inc. Eli Lilly and Company [Member] Represents the information pertaining to license agreement with Eli Lilly and Company (Lilly), which has given the entity exclusive rights to develop, market, promote and commercialize Adcirca. Eli Lilly and Company Toray Industries, Inc. [Member] Represents the information pertaining to license agreement with Toray to obtain exclusive rights to develop and market beraprost, a chemically stable oral prostacyclin analogue. Toray Industries, Inc. Other License Agreements [Member] Represents the information pertaining to other license agreements relating to the entity's key therapeutic platforms and to other therapeutic platforms. Other Royalty Payment Term Minimum term of royalty payment Represents the minimum royalty payment term. Represents the installment payment term under the license agreement. Term of installment payments under license License Installment Payment Term Collaborative Arrangement, Common Stock Repurchase Price Per Share Price per share (in dollars per share) Represents the price per share the entity must pay on the repurchase of common stock issued to the counterparty of a collaborative agreement. The repurchase is at the discretion of the counterparty. Percentage of Reduction in Royalty Payment, Maximum Reduction in royalty percentage in the event of payment to third party Represents the reduction in royalty percentage in the event of payment to third party. Royalty Payment Obligation Amount Obligation and a corresponding charge to research and development expenses Represents the present value of the total obligation and corresponding charge to research and development expense. Royalty payments, remaining obligation Represents the remaining obligation amount of royalty payments. Royalty Payment, Remaining Obligation Amount Represents the minimum annual net sales for payment of royalty. Minimum Annual Net Sales for Payment of Royalty Minimum annual net sales for payment of royalty Assignment and License Agreements Kurzweil Technologies, Inc. [Member] Details pertaining to Kurzweil Technologies, Inc. (KTI), a company controlled by Raymond Kurzweil. Kurzweil Technologies, Inc. Related Party Transaction, Royalty Rate Percentage of royalty agreed to be paid Represents the stated royalty rate as per the agreement. Related Party Transaction Royalty Rate, Maximum Percentage of royalty agreed to be paid, maximum Represents the maximum stated royalty rate as per the agreement. Revivicor, Inc. [Member] Details pertaining to Revivicor, Inc., a company focused on developing genetic biotechnology platforms. Revivicor, Inc. Tyvaso Inhalation System [Member] Represents the details pertaining to the acquisition of Tyvaso Inhalation System. Tyvaso Inhalation System Represents the milestone payments contingent upon receiving regulatory approvals. Milestone payments contingent upon receiving regulatory approvals Business Acquisition Contingent Milestone Payments on Receiving Regulatory Approvals Accrued Liabilities, Current [Abstract] Accrued Expenses Schedule of Disposal Groups Revenue and Loss [Table Text Block] Revenues and loss before income tax of Medicomp, Inc. Tabular disclosure of disposal groups, which includes the amounts of revenues and pretax profit or loss reported in discontinued operations. Medicomp, Inc. [Member] Represents details pertaining to Medicomp, Inc., a wholly owned telemedicine subsidiary of the entity. Medicomp, Inc. (Medicomp) Disposal Group, Outstanding Stock Sold Percentage Represents the percentage of outstanding stock sold in the sale of a business. Dispositions, stock sold percentage Disposal Group Including Discontinued Operation Consideration Received in Shares Dispositions, consideration received (in shares) Shares received in the sale of a business. Dispositions, aggregate value of common stock received Disposal Group, Value of Common Stock Received Represents the aggregate value of common stock received in the disposition of a business. Dispositions, consideration received, promissory note Promissory note received in the sale of a business. Disposal Group Including Discontinued Operation Consideration Received Promissory Note Length of the term of the promissory note received in the sale of a business. Length of promissory note term Promissory Note Period Promissory Note, Interest Rate, Stated Percentage Promissory note, stated percentage Represents the stated interest rate of the promissory note. Percentage of Ownership Interest Held after Sale Percentage of ownership interest acquired after sale Represents the percentage of the entity's ownership interest acquired in the disposed business subsequent to its sale. Ownership Interest Acquired after Sale Cash Paid Ownership interest acquired after sale, cash paid Represents cash paid by the entity subsequent to the sale of the business to acquire an interest in the aforementioned business. Ownership Interest Acquired after Sale Reduction to Face Value of Promissory Note Ownership interest acquired after sale, reduction to face value of promissory note Represents the reduction in the face value of the promissory note from the disposed entity subsequent to the sale of the business to acquire an interest in the aforementioned business. Discontinued Operation, Period During which Criteria for Reporting as Discontinued Operations Represents the assessment period for evaluating the disposal of a component to determine whether the criteria is met to be reported as a Discontinued Operation. Number of years for assessing whether disposal should be reported within discontinued operations Disposal Group, Including Discontinued Operation, Accounts, Receivable and Inventory Accounts receivable and inventory Represents the disposal group, including a component of the entity (discontinued operation), the aggregate of amounts due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection and net of any write-downs taken for collection uncertainty on the part of the holder, respectively. It also includes a component of the entity (discontinued operation), carrying amount of inventories (net of all valuation allowances and write-downs). UNITED STATES United States Revenues and loss before income tax Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract] Represents the investment, at cost, in a telemedicine-related third party. Investments held in another telemedicine-related company Investment Owned at Cost in Third Party Capital Loss from Disposal of Business Not Discontinued Operation Represents the capital loss recognized for tax purposes as a result of the excess of tax basis over the book value of the business sold. Capital loss recognized for tax purposes Capital Loss from Disposal of Business Not Discontinued Operation, Deferred Tax Asset Fully Reserved Represents the deferred tax asset generated by the capital loss recognized for tax purposes as a result of the excess of tax basis over the book value of the business sold. The deferred tax asset has been fully reserved. Deferred tax asset, fully reserved Equity Incentive Plan Equity Incentive Plan [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Contractual Term, Maximum Term of employee stock purchase plan Represents the maximum contractual term of options granted under the equity incentive plan which are nontransferable. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Period, Maximum Represents the maximum volatility period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. Expected volatility maximum period Shareholders Rights Plan [Abstract] Shareholder Rights Plan Class of Warrant or Right Purchase Price of Right before Amendment and Restatement Purchase price of each Right, before the amendment and restatement of the Rights (in dollars per one one-thousandth of a share) Represents the purchase price of each right before the amendment and restatement of the rights. Represents the purchase price of each right after the amendment and restatement of the rights. Class of Warrant or Right Purchase Price of Right after Amendment and Restatement Purchase price of each Right, after the amendment and restatement of the Rights (in dollars per one one-thousandth of a share) Class of Warrant or Right Shares of Series A Junior Participating Preferred Stock Per Right Represents the number of shares of Series A Junior Participating Preferred Stock each right entitles a holder to purchase. Number of shares of Series A Junior Participating Preferred Stock each Right entitles a holder to purchase Class of Warrant or Right Condition on Exercise of Rights Minimum Percentage of Common Stock to be Acquired in Tender Offer Minimum ownership percentage in the outstanding shares of voting stock from the commencement of a tender offer that would result in the exercise of shares under one condition of the Agreement (as a percent) Represents the Minimum ownership percentage in the outstanding shares of voting stock from the commencement of a tender offer that would result in the exercise of shares under one condition of the agreement. The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to incentive stock option expense under enacted tax laws during the period. Income Tax Reconciliation, Incentive Stock Option Expense Incentive stock option expense License fees capitalized for tax purposes The tax effect as of the balance sheet date of the amount of the estimated future tax deductions attributable to license fees capitalized, which can only be realized, if sufficient tax-basis income is generated in future periods to enable the deduction to be taken. Deferred Tax Assets Capitalized License Fees Deferred Tax Assets, Nonqualified Stock Options Nonqualified stock options The tax effect as of the balance sheet date of the amount of the estimated future tax deductions attributable to nonqualified stock options, which can only be realized, if sufficient tax-basis income is generated in future periods to enable the deduction to be taken. Deferred Tax Assets, Supplemental Executive Retirement Plan SERP The tax effect as of the balance sheet date of the amount of the estimated future tax deductions attributable to supplemental executive retirement plan (SERP), which can only be realized, if sufficient tax-basis income is generated in future periods to enable the deduction to be taken. The tax effect as of the balance sheet date of the amount of the estimated future tax deductions attributable to share tracking awards plan (STAP), which can only be realized, if sufficient tax-basis income is generated in future periods to enable the deduction to be taken. Deferred Tax Assets, Share Tracking Awards Plan STAP awards Represents the gross amount of net deferred tax assets before valuation allowance as of the balance sheet date, which results from applying the applicable enacted tax rate to net temporary differences and carryforwards pertaining to assets or liabilities. A temporary difference is a difference between the tax basis of an asset or liability and its carrying amount in the financial statements prepared in accordance with generally accepted accounting principles that will reverse in ensuing periods. Deferred Tax Assets, Net, before Valuation Allowance Net deferred tax asset before valuation allowance Unrecognized Tax Benefits Increase (Decrease) Resulting from Settlements with Taxing Authorities Settlements The gross amount of increase (decrease) in unrecognized tax benefits resulting from settlements with taxing authorities. Pharmaceutical Represents information pertaining to the pharmaceutical segment. Pharmaceutical [Member] Recently Issued Accounting Standards New Accounting Pronouncements, Adopted, Disclosure [Text Block] Recently Issued Accounting Standards Represents the recently issued accounting standards. Describes the terms of license agreements including milestones, fees and royalties the company is, or may be required to pay under the agreements. Assignment and License Agreements Assignment and License Agreements [Text Block] Schedule of Distribution Agreements [Table] Disclosure pertaining to the distribution agreements. Distribution Agreements [Axis] Disclosure pertaining to the distribution agreements with the U.S.-based specialty pharmaceutical distributors. Distribution Agreements [Domain] Disclosure pertaining to the distribution agreements with the U.S.-based specialty pharmaceutical distributors for various products of the entity. U.S. Based Specialty Pharmaceutical Distributors U.S. Based Specialty Pharmaceutical [Member] Details pertaining to distribution agreements for Tyvaso with U.S.-based specialty pharmaceutical distributors. Mochida Pharmaceutical Co., Ltd. Mochida Pharmaceutical [Member] Details pertaining to exclusive agreement with Mochida Pharmaceutical Co., Ltd. (Mochida) for distribution of subcutaneous and intravenous remodulin in Japan. Distribution Agreements [Line Items] Distribution Agreements Distribution Agreements, Initial Term Distribution agreement, initial term Represents the initial term for distribution agreement. Distribution Agreements, Additional Term Distribution agreement, additional terms Represents the additional terms for distribution agreement unless terminated earlier. Proceeds from Distribution Agreements Payments received pursuant to distribution agreement Represents the amount received during the period pursuant to distribution agreements. Future milestone payments Represents the future milestone payments upon achievement of certain milestones. Distribution Agreements, Future Milestone Payments Accrued Liabilities, Current Accrued expenses Total Share Based Compensation Arrangement by Share Based Payment Award Expiration Term Grant expiration period from the grant date The period when the equity-based award expires as specified in the award agreement. Increase (Decrease) in Insurance Proceeds Receivable Insurance proceeds receivable (Note 13) Represents increase decrease in insurance proceeds receivable during the reporting period. Gain Contingency Maximum Payment Terms of Settlement Agreement from the Date of Execution of Agreement Period from the date of execution in which settlement agreement amount will be paid Represents the maximum period of which Insurance entity agrees to pay from the date of execution of the agreement. Accumulated Other Comprehensive Income (Loss) [Member] Accumulated Other Comprehensive Income/(Loss) Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less-accumulated depreciation Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Additional Paid in Capital, Common Stock Additional paid-in capital Additional Paid-in Capital [Member] Additional Paid-in Capital Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature Issuance of 2016 convertible notes (Note 8) Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation Tax benefit from exercises of non-qualified stock options Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Share-based compensation Allocated Share-based Compensation Expense, Net of Tax Share-based compensation expense (benefit), net of taxes Allocated Share-based Compensation Expense Share-based compensation expense (benefit) before taxes Share-based compensation expense before taxes Allowance for Doubtful Accounts Receivable, Current Accounts receivable, allowance (in dollars) Amortization of Intangible Assets Aggregate amortization expense relating to intangible assets Amortization of Debt Discount (Premium) Discount amortization Amortization of Financing Costs and Discounts Amortization of debt discount and debt issue costs Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Stock options and warrants excluded from calculation (in shares) Asset Impairment Charges Impairments Assets, Fair Value Disclosure Total assets Assets, Current [Abstract] Current assets: Assets [Abstract] Assets Assets of Disposal Group, Including Discontinued Operation Total assets Assets, Current Total current assets Assets Total assets Assets of Disposal Group, Including Discontinued Operation [Abstract] Assets Assets, Fair Value Disclosure [Abstract] Assets Auction Rate Securities [Member] Auction-rate Securities Available-for-sale Securities, Fair Value Disclosure Available-for-sale equity investment Basis of Accounting [Text Block] Basis of Presentation Building Improvements [Member] Building improvements Building [Member] Buildings Business Acquisition [Axis] Business Acquisition, Cost of Acquired Entity, Cash Paid Initial payment in cash Business Acquisition, Purchase Price Allocation, Net Tangible Assets Fair value of net tangible assets acquired Business Acquisition, Contingent Consideration, at Fair Value Contingent consideration at fair value Business Acquisition, Purchase Price Allocation, Goodwill Amount Fair value of goodwill Goodwill Business Acquisition, Percentage of Voting Interests Acquired Acquisition of outstanding stock (as a percent) Percentage of outstanding stock acquired (as a percent) Business Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net [Abstract] Acquisition date fair value of the assets acquired and liabilities assumed Business Acquisition, Purchase Price Allocation, Tangible Assets Tangible assets Business Acquisition, Contingent Consideration, Potential Cash Payment Additional consideration upon the achievement of specific developmental and regulatory milestones Maximum contingent consideration upon achievement of milestones Business Acquisition, Acquiree [Domain] Business Acquisition, Purchase Price Allocation, Liabilities Assumed Total liabilities assumed Business Combinations [Abstract] Business Acquisition, Purchase Price Allocation, Amortizable Intangible Assets Fair value of net contract-based intangible assets acquired Identifiable intangible assets Business Acquisition, Purchase Price Allocation, Current Liabilities Current liabilities Business Acquisition, Purchase Price Allocation, Assets Acquired Total assets acquired Business Acquisition, Purchase Price Allocation, Noncurrent Liabilities Long-term liabilities Business Acquisition [Line Items] Acquisitions Business Combination Disclosure [Text Block] Acquisitions Capital Expenditures Incurred but Not yet Paid Non-cash additions to property, plant and equipment Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash and cash equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Cash Equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net increase in cash and cash equivalents Cash and Cash Equivalents [Abstract] Cash Equivalents Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash investing activities: Chief Executive Officer [Member] Chief Executive Officer (CEO) Class of Warrant or Right, Exercise Price of Warrants or Rights Share warrant, exercise price (in dollars per share) Class of Stock [Domain] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Share warrant, number of shares Number of securities called by warrants or rights (in shares) Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Research agreement Assignment and License Agreements Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain] Collaborative Arrangements and Non-collaborative Arrangements [Axis] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments and contingencies: Common Stock [Member] Common Stock Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Value, Issued Common stock, par value $.01, 245,000,000 shares authorized, 61,892,578 and 61,506,063 shares issued, and 51,162,680 and 53,609,645 shares outstanding at September 30, 2012 and December 31, 2011, respectively Common Stock, Shares, Issued Common stock, shares issued Common stock issued (in shares) Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Supplemental Executive Retirement Plan Components of Deferred Tax Assets [Abstract] Deferred tax assets: Components of Deferred Tax Assets and Liabilities [Abstract] Components of net deferred tax asset Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income Comprehensive Income (Loss) Note [Text Block] Comprehensive Income Comprehensive Income [Member] Comprehensive Income Concentration Risk Type [Domain] Concentrations of Credit Risk, Products, Revenues and Customers Concentration Risk [Line Items] Segment Information Concentration Risk Benchmark [Domain] Concentration Risk [Table] Concentration Risk Benchmark [Axis] Concentration Risk Type [Axis] Concentration Risk, Percentage Concentration risk, percentage Construction in Progress [Member] Buildings under construction Convertible Debt [Member] Convertible Senior Notes Convertible Notes Payable, Current Convertible notes Convertible Notes Payable, Noncurrent Convertible notes Convertible Debt, Fair Value Disclosures Convertible Senior Notes Corporate Debt Securities [Member] Corporate notes and bonds Cost of Goods Sold Cost of product sales Cost of revenues Cost of Sales [Member] Cost of service sales Cost of product sales Cost-method Investments, Aggregate Carrying Amount Investments in equity of privately-held corporations Cost of Services Cost of service sales Costs and Expenses [Abstract] Operating expenses: Costs and Expenses Total operating expenses Credit Concentration Risk [Member] Credit concentration Current State and Local Tax Expense (Benefit) State Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Current: Current Income Tax Expense (Benefit) Total current Current Foreign Tax Expense (Benefit) Foreign Current Federal Tax Expense (Benefit) Federal Customer Concentration Risk [Member] Customer concentration Debt Instrument, Description of Variable Rate Basis Debt, floating rate of interest basis Long-term Debt, Gross Principal balance Debt Instrument [Line Items] Debt Schedule of Long-term Debt Instruments [Table] Debt Security [Axis] Debt Disclosure [Text Block] Debt Debt Debt Instrument, Convertible, Conversion Price Conversion price (in dollars per share) Debt Instrument, Basis Spread on Variable Rate Debt, floating rate of interest, basis spread (as a percent) Debt Instrument, Increase, Additional Borrowings Debt aggregate principal value Debt Instrument, Unamortized Discount Convertible debt, discount to reduce net carrying value Debt Instrument, Convertible, Interest Expense Interest expense-convertible notes Debt Instrument, Interest Rate at Period End Debt, interest rate at period end (as a percent) Debt Instrument, Interest Rate, Stated Percentage Convertible Senior Notes, stated percentage Title of Individual [Axis] Deferred Federal Income Tax Expense (Benefit) Federal Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Deferred Deferred Foreign Income Tax Expense (Benefit) Foreign Deferred Income Tax Expense (Benefit) Total deferred Current and deferred income tax expense Deferred Tax Assets, Net of Valuation Allowance Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance, Current Deferred tax assets Deferred Tax Assets, Gross Total deferred tax assets Deferred State and Local Income Tax Expense (Benefit) State Deferred Tax Assets, Unrealized Losses on Trading Securities Realized losses on marketable investments Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses Impairment losses on investments Deferred Tax Assets, Other Other Deferred Tax Assets, Tax Credit Carryforwards, General Business Business tax credit carryforwards Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Deferred tax assets, net Deferred Tax Assets, Valuation Allowance Valuation allowance Deferred Tax Liabilities, Other Other Deferred Tax Liabilities, Property, Plant and Equipment Plant and equipment principally due to differences in depreciation Deferred Tax Liabilities, Gross [Abstract] Deferred tax liabilities: Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost, before Tax Net unrecognized prior service cost Defined Benefit Plan, Accumulated Benefit Obligation Accumulated benefit obligation Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Salary Increases (as a percent) Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Amoritization of prior service costs Defined Benefit Plan, Expected Future Benefit Payments, Year Three 2014 Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Reconciliation of beginning and ending balances of the projected benefit obligation Defined Benefit Plan, Amortization of Net Prior Service Cost (Credit) Amortization of prior service cost Defined Benefit Plan, Actuarial Gain (Loss) Actuarial (gain) loss Pension and Other Postretirement Benefit Plans, Amounts that Will be Amortized from Accumulated Other Comprehensive Income (Loss) in Next Fiscal Year [Abstract] Amounts included in accumulated other comprehensive income expected to be recognized as components of net periodic pension cost Defined Benefit Plan, Amortization of Net Gains (Losses) Amortization of net actuarial (gain) loss Defined Benefit Plan, Expected Future Benefit Payments, Year Two 2013 Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract] Amounts relating to the SERP that have been recognized in other comprehensive income Defined Benefit Plan, Expected Future Benefit Payments, Year Five 2016 Total Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), before Tax Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Gains (Losses), before Tax Net unrecognized actuarial (gain) loss Defined Benefit Plan, Expected Future Benefit Payments, Year Four 2015 Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Discount Rate (as a percent) Defined Benefit Plan, Expected Future Benefit Payments, Next Twelve Months 2012 Defined Benefit Plan, Amortization of Gains (Losses) Amortization of net actuarial loss Defined Benefit Plan Disclosure [Line Items] Supplemental Executive Retirement Plan Disclosure Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), before Tax [Abstract] Accumulated other comprehensive income (loss) that have not yet been recognized as a component of net periodic pension cost Defined Benefit Plan, Benefit Obligation Projected benefit obligation at the end of the period Projected benefit obligation at the beginning of the period Pension and Other Postretirement Benefit Plans, Amounts that Will be Amortized from Accumulated Other Comprehensive Income (Loss) in Next Fiscal Year Total